Trial reportWorld journal of gastroenterology2019
Two-week bismuth-containing quadruple therapy and concomitant therapy are effective first-line treatments for
Trial report in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- [Evidence-Based Guidelines for the Diagnosis and Treatment ofThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi · 2026Guideline
- Guideline
- Use of an abdominal binder in colonoscopies performed by trainees in gastrointestinal endoscopy: a randomized, double-blind, sham-controlled trial.Surgical endoscopy · 2025Trial
- Fourteen-day vonoprazan-based bismuth quadruple therapy for H. pylori eradication in an area with high clarithromycin and levofloxacin resistance: a prospective randomized study (VQ-HP trial).Scientific reports · 2024Trial
- Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.BMC gastroenterology · 2021Trial
- Evidence-Based Guidelines for the Diagnosis and Treatment of Helicobacter pylori Infection in Korea: 2025 Revised Edition.The Korean journal of helicobacter and upper gastrointestinal research · 2026Review
- Review Article: Classic Bismuth Quadruple Therapy for Helicobacter pylori Infection-Questions Focused on Clinical Practice.Alimentary pharmacology & therapeutics · 2026Review
- Comparison of bismuth and concomitant therapy forFuture science OA · 2025Article
- Addressing the global challenge ofGut microbes reports · 2025Article
- High-dose amoxicillin and pantoprazole regimen forPrzeglad gastroenterologiczny · 2025Article
- Comparison of tegoprazan-based high-dose dual therapy versus bismuth-containing quadruple therapy forTherapeutic advances in gastroenterology · 2025Article
- Comparison of Amoxicillin Administered Twice versus Four Times a Day in First-LineMicroorganisms · 2024Article
- Concomitant and Bismuth Quadruple Therapy forAntibiotics (Basel, Switzerland) · 2024Article
- Novel therapeutic regimens againstFrontiers in microbiology · 2024Review
- The preventative effects ofFrontiers in microbiology · 2024Article
- Use of eradication therapy in adjunction to periodontal therapy versus alone for treatment ofAnnals of medicine and surgery (2012) · 2023Article
- Standard Bismuth Quadruple Therapy versus Concomitant Therapy for the First-Line Treatment ofJournal of clinical medicine · 2023Review
- Helicobacter Pylori: A Review of Current Treatment Options in Clinical Practice.Life (Basel, Switzerland) · 2022Review
- Tailored eradication strategyWorld journal of gastroenterology · 2021Article
- The status and progress of first-line treatment againstTherapeutic advances in gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIncreasing levels of antibiotic resistance have reduced the
aimTo analyze the eradication rates of modified bismuth-containing quadruple therapy (mBCQT) and concomitant therapy (CT), the associated adverse events, and compliance.
methodsPatients infected with
resultsThe demographic characteristics of 68 patients who received mBCQT and 68 who received CT did not differ significantly. On intention-to-treat analysis, the eradication rate was 88.2% (60/68) in the mBCQT group and 79.4% (54/68) in the CT group (
conclusionThe
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.